#ACC21: Bris­tol My­ers backs up its case for heart drug mava­camten as FDA weighs app in car­diomy­opa­thy

When Bris­tol My­ers Squibb signed off on its $13 bil­lion ac­qui­si­tion of MyoKar­dia back in Oc­to­ber, it was mak­ing a big bet that lead drug mava­camten could prove a game chang­er in car­diac my­opa­thy. Now, with the drug up for FDA re­view, Bris­tol My­ers is back­ing up its case with new qual­i­ty of life da­ta.

Pa­tients dosed with myosin in­hibitor mava­camten post­ed a clin­i­cal­ly sig­nif­i­cant in­crease in scores on the Kansas City Car­diomy­opa­thy Ques­tion­naire, a catch-all sum­ma­ry of symp­toms and qual­i­ty of life mark­ers, over place­bo at 30 weeks, ac­cord­ing to da­ta from the Phase III EX­PLOR­ER-HCM study pre­sent­ed Sat­ur­day at the vir­tu­al Amer­i­can Col­lege of Car­di­ol­o­gy meet­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.